Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: SAE battery
Behavioral: Assessments

First Posted Date: 2018-08-07

Last Posted Date: 2025-01-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 187

Registration Number: NCT03619083

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

Phase 1

Active, not recruiting

Conditions: Upper Tract Urothelial Carcinoma

Interventions: Drug: WST11 mediated vascular targeted phototherapy (VTP)
Procedure: Endoscopy

First Posted Date: 2018-08-06

Last Posted Date: 2024-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03617003

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoid Leukemia (ALL)
Chronic Myeloid Leukemia (CML)
Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)

Interventions: Radiation: Hyperfractionated total body irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Fludarabine
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Clofarabine
Procedure: HPC(A) stem cell allograft
Drug: Rituximab
Device: Rabbit antithymocyte globulin

First Posted Date: 2018-08-03

Last Posted Date: 2024-03-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03615105

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Phase 2

Terminated

Conditions: Non-Malignant Hematologic Disorders

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Clofarabine
Drug: Fludarabine
Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Procedure: CliniMACS reagents

First Posted Date: 2018-08-03

Last Posted Date: 2021-03-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT03615144

Locations: 🇺🇸
Memorial SloanKettering Cancer Center, New York, New York, United States

Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors

Not Applicable

Active, not recruiting

Conditions: Brain Tumor

Interventions: Device: fMRI Paradigms

First Posted Date: 2018-07-27

Last Posted Date: 2024-01-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 33

Registration Number: NCT03604302

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)
Fanconi Anemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Anti-Thymocyte Globulin (Rabbit)
Device: The CliniMACS device
Drug: G-CSF

First Posted Date: 2018-07-26

Last Posted Date: 2022-04-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03600909

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Phase 2

Recruiting

Conditions: Sezary Syndrome
Mycosis Fungoides
Lymphomatoid Papulosis

Interventions: Drug: brentuximab vedotin

First Posted Date: 2018-07-16

Last Posted Date: 2023-12-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT03587844

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Phase 1

Active, not recruiting

Conditions: Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Interventions: Drug: Ibrutinib
Drug: Copanlisib

First Posted Date: 2018-07-10

Last Posted Date: 2024-02-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT03581942

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel 60 mg/m2
Drug: Docetaxel 75 mg/m2
Drug: Radium-223

First Posted Date: 2018-07-02

Last Posted Date: 2025-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 738

Registration Number: NCT03574571

Locations: 🇺🇸
Millennium Physicians, Houston, Texas, United States
🇪🇸
Vall d'Hebron Institute of Oncology (VHIO) (Data Collection Only), Barcelona, Spain
🇪🇸
Clinic de Barcelona, Barcelona, Spain

and more 68 locations

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Other: Information Booklet
Other: TEAMWork App

First Posted Date: 2018-06-28

Last Posted Date: 2024-07-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 546

Registration Number: NCT03572374

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent and Follow-up), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and Follow-up), Basking Ridge, New Jersey, United States
🇺🇸
Queens Cancer Center of Queens Hospital, Jamaica, New York, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy